Send to

Choose Destination
Haematologica. 2019 May;104(5):864-867. doi: 10.3324/haematol.2018.214536.

Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?

Author information

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Division of Hematopathology, Department of Pathology, University of Virginia, Charlottsville, VA, USA.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center